ESTRO 2024 - Abstract Book

S665

Clinical - Breast

ESTRO 2024

Conclusion:

Under a prospective clinical trial, in selected patients, IOERT with a total dose of 20Gy is safe and effective. Patients with Luminal A and Luminal B like subtypes mostly presented a low stromal percentage of TILs.

Keywords: TILs, breast cancer, intraoperative radiotherapy

References:

1-Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S; International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015 Feb;26(2):259 71. doi: 10.1093/annonc/mdu450.

2-Criscitiello, C., Vingiani, A., Maisonneuve, P. et al. Tumor- infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer. Breast Cancer Res Treat 183, 347 – 354 (2020). https://doi.org/10.1007/s10549-020-05771-7.

2699

Digital Poster

Hypofractionated WBI With or Without Hypofractionated Boost: Late Toxicity and Treatment Outcomes